Chimerix, 2505 Meridian Pkwy, Suite 100, Durham, NC 27713, United States.
Novartis, Cambridge, MA, United States.
Drug Metab Lett. 2021;14(2):126-136. doi: 10.2174/1872312814666210405101419.
A group of substituted benzothiazoles from a research project was found to have low microsomal clearance. However, these compounds had very high clearance in vivo.
In the present study, the clearance mechanism of two of the structural analogs, was investigated in vitro and in vivo.
In vitro studies showed the formation of corresponding non-P450 dependent oxidative metabolites in S9, cytosol, and hepatocytes. The in vitro formation of these metabolites was observed in mice, rats, non-human primates, and humans. The dog did not form the corresponding metabolites in any of the matrices. Inhibition studies with S9 fraction and incubation with human recombinant aldehyde oxidase (AO) showed that the formation of the corresponding metabolites was AO dependent. To investigate the role of this pathway in vivo, mice were dosed with compound A and bile and plasma were analyzed. Most of the metabolites in bile contained the AO-dependent oxidized benzothiazole moiety, indicating that metabolism involving AO was probably the main pathway for clearance. The same metabolites were also observed circulating in plasma. Mass spectrometric analysis of the metabolite showed that the oxidation was on the benzothiazole moiety, but the exact position could not be identified. Isolation of the metabolite of compound A and analysis by NMR confirmed the structure of the metabolite as C2 carbon oxidation of the thiazole ring resulting in carboxamide moiety. Further comparison of both metabolites with corresponding authentic standards confirmed the structures.
To our knowledge, such an observation of in vitro and in vivo oxidation of substituted benzothiazole by AO has not been reported before. The results helped the medicinal chemists design compounds that avoid AO-mediated metabolism and with better ADME property.
从一个研究项目中发现一组取代的苯并噻唑类化合物的微粒体清除率较低。然而,这些化合物在体内的清除率却非常高。
在本研究中,两种结构类似物的清除机制在体外和体内进行了研究。
体外研究表明,在 S9、胞浆和肝细胞中形成相应的非 P450 依赖性氧化代谢物。在小鼠、大鼠、非人类灵长类动物和人中观察到这些代谢物的体外形成。在任何基质中,狗都没有形成相应的代谢物。用 S9 级分进行抑制研究和用人重组醛氧化酶(AO)孵育表明,相应代谢物的形成依赖于 AO。为了研究该途径在体内的作用,用化合物 A 对小鼠进行了给药,并分析了胆汁和血浆。胆汁中的大多数代谢物都含有 AO 依赖性氧化的苯并噻唑部分,表明涉及 AO 的代谢可能是清除的主要途径。同样的代谢物也在血浆中循环。对代谢物的质谱分析表明,氧化发生在苯并噻唑部分,但确切位置无法确定。化合物 A 的代谢物的分离和 NMR 分析证实了代谢物的结构为噻唑环的 C2 碳氧化,导致羧酰胺部分。与相应的纯标准品对这两种代谢物的进一步比较证实了它们的结构。
据我们所知,以前没有报道过 AO 体外和体内氧化取代的苯并噻唑的这种观察结果。这些结果帮助药物化学家设计出避免 AO 介导的代谢并具有更好的 ADME 性质的化合物。